Clinical Trials Sponsored by Emergent BioSolutions

Total 668 results

Emergent BioSolutions

Completed

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)

Smallpox

United States
Emergent BioSolutions

Terminated

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

T-cell Lymphoma
Emergent BioSolutions

Terminated

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Healthy Volunteers

United States
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
Emergent BioSolutions

Completed

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

Smallpox

United States
Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
Emergent BioSolutions

Completed

VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

Canada
Emergent BioSolutions

Completed

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

Opioid Overdose

United States
Emergent BioSolutions

Completed

Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

Zika Virus Infection | Zika Virus Disease

Canada
Emergent BioSolutions

Completed

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

T Cell Lymphoma
Emergent BioSolutions

Enrolling by invitation

BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients

Botulism
Emergent BioSolutions

Completed

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Typhoid

United States
Emergent BioSolutions

Completed

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Influenza A H3N2 | Influenza A H1N1

United States, Spain, Canada, Puerto Rico
Emergent BioSolutions

Completed

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

Smallpox

United States
Emergent BioSolutions

Completed

ACAM2000® Myopericarditis Registry

Myocarditis | Pericarditis

United States
Emergent BioSolutions

Completed

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Emergent BioSolutions

Completed

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

Anthrax Infection

United States
Emergent BioSolutions

Completed

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

Smallpox

United States
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
Emergent BioSolutions
GlaxoSmithKline

Completed

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

Infections, Bacterial

United States
Bavarian Nordic
Emergent BioSolutions

Completed

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Typhoid Fever

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine (CHIKV VLP)

Chikungunya Virus

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Cholera

United States
Bavarian Nordic
Emergent BioSolutions

Completed

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Cholera (Disorder)

United States
Bavarian Nordic
Emergent BioSolutions

Completed

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Cholera

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

Chikungunya Virus

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Cholera

United States, Australia
Bavarian Nordic
Emergent BioSolutions

Completed

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Chikungunya Virus Infection

United States
Bavarian Nordic
Emergent BioSolutions

Completed

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Cholera

United States
Valneva Austria GmbH
Emergent BioSolutions

Completed

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

Zika Virus Infection | Zika Virus

United States
Emergent BioSolutions
Naval Health Research Center

Completed

BioThrax® (Anthrax) Vaccine in Pregnancy Registry

Congenital Abnormalities | Pregnancy Complications | Pregnancy Outcome

United States
Emergent BioSolutions
Quintiles, Inc.; Unither Virology

Completed

Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects (UV)

Viral Infection

United States
Pfizer
Trubion Pharmaceuticals/Emergent BioSolutions Inc.

Terminated

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Germany, Hungary, Serbia, Belgium, France, Netherlands, Mexico, Canada, Romania
Emergent BioSolutions
National Institutes of Health (NIH)

Completed

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

Anthrax

United States
Human Genome Sciences Inc.
GlaxoSmithKline; Emergent BioSolutions

Completed

An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection

Therapeutic Treatment of Inhalation Anthrax
Human Genome Sciences Inc.
GlaxoSmithKline; Emergent BioSolutions

Completed

A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects

Healthy
Emergent BioSolutions
United States Department of Defense

Completed

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults

SARS-CoV-2 Infection

United States
Emergent BioSolutions
United States Department of Defense

Completed

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

COVID-19

United States
Emergent BioSolutions
National Institutes of Health (NIH)

Completed

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

Anthrax

United States
Emergent BioSolutions
Department of Health and Human Services

Completed

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

Anthrax

United States
Emergent BioSolutions
Centers for Disease Control and Prevention

Enrolling by invitation

VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

Complication of Smallpox Vaccination
Emergent BioSolutions
Biomedical Advanced Research and Development Authority

Completed

Study of SIAN Nasal Spray in Healthy Adults

Cyanide Poisoning

United States
Emergent BioSolutions
Department of Health and Human Services

Completed

Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle

Healthy Volunteers

United States
Emergent BioSolutions
Biomedical Advanced Research and Development Authority

Completed

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

Anthrax

United States
Emergent BioSolutions
Centers for Disease Control and Prevention

Completed

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

United States
Emergent BioSolutions
Biomedical Advanced Research and Development Authority

Completed

VELOCITY: An Anthrax Vaccine Clinical Study

Anthrax

United States
Emergent BioSolutions
Department of Health and Human Services

Completed

Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

Healthy

United States
Emergent BioSolutions
Department of Health and Human Services

Completed

Ciprofloxacin BioThrax Co-Administration Study

Anthrax

United States
Emergent BioSolutions
Department of Health and Human Services

Completed

Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

Symptoms of Inhalational Anthrax

United States
Bavarian Nordic
Emergent BioSolutions; Catalyst Clinical Research, LLC

Completed

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Chikungunya Virus

United States

Clinical Trials Sponsored by Emergent BioSolutions

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations